Cargando…
A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome
Chronic lymphocytic leukemia (CLL) is a progressive disease with an indolent course, and tumor lysis syndrome (TLS) is rarely seen in CLL. Ibrutinib is a novel bruton kinase (BTK) inhibitor increasingly used in CLL treatment. Ibrutinib has significant side effects such as atrial fibrillation, bleedi...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Istanbul Medeniyet University
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226401/ https://www.ncbi.nlm.nih.gov/pubmed/34239769 http://dx.doi.org/10.5222/MMJ.2021.56424 |